Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049774 | 0.83 | ALDH1A1 (0.46) | KDM4EALDH1A1GAAALOX15RAB9A | |
| SCHEMBL30682542 | 0.80 | HPGD (0.55) | NAMPTCYP17A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL29614703 | 0.78 | MEN1 (0.45) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4252286 | 0.78 | MEN1 (0.45) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28408407 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1GAAALOX15RAB9A | |
| SCHEMBL30448414 | 0.77 | AXL (0.48) | RAB9ASMN1; SMN2NPC1LMNAKMT2A | |
| SCHEMBL30448108 | 0.77 | RAB9A (0.46) | ALDH1A1RAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL30448073 | 0.76 | KMT2A (0.51) | NAMPTKDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13855103 | 0.76 | RAF1 (0.66) | MEN1KMT2ARAF1EPHX2 | |
| SCHEMBL29131710 | 0.75 | HPGD (0.59) | NAMPTCYP17A1ALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | NAMPT 416/4885METAP1 3236/4885CYP17A1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.